The purpose of the study is to study the prognostic role of NT¬proBNP in patients with diabetes mellitus type 2 associated chronic heart failure (CHF).
Material and research methods: For the period 2015-2021, 185 patients were identified as an object of study, and 185 patients based on the materials of their preparations into therapeutic and prophylactic institutions of Andijan from 30 years and older. Patients were distributed to 3 groups: 1 Group are patients with DM 2 type + CHF - 65 patients, 2 Group are patients with DM 2 type without CHF - 60 patients, 3 Group - these are patients with CHF without DM 2 type - 60 patients Patients were fulfilled with general, biochemical, hormonal, genetic blood tests, as well as ECG, ECHC and other instrumental research.
Results of the study: The average values of NT-proBNP were significantly different in all groups and at the same time they were significantly higher in the group of patients with DM2 + CHF compared with the parameters of the patients with insulated CHF. We selected median levels of NT-proBNP in increasing NT-proBNP treads ranging from 125 to 250 pg/ml, from 250 to 500 pg/ml and above 500 pg/ml.
Conclusions: Increasing the concentration of NT-proBNP in all patients of DM 2 with CHF, as well as the high sensitivity and specificity of the test dough, the value of this marker for the diagnosis of CHF in patients with a 2-type diagnosis. The dynamics of their concentration, mainly NT-proBNP, can help in assessing the effectiveness of the therapy and the need for dose of drugs.
21 May 2022 - 24 May 2022